IL265700B2 - N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4 -tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea and its uses - Google Patents

N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4 -tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea and its uses

Info

Publication number
IL265700B2
IL265700B2 IL265700A IL26570019A IL265700B2 IL 265700 B2 IL265700 B2 IL 265700B2 IL 265700 A IL265700 A IL 265700A IL 26570019 A IL26570019 A IL 26570019A IL 265700 B2 IL265700 B2 IL 265700B2
Authority
IL
Israel
Prior art keywords
compound
treatment
estradiol
use according
endometriosis
Prior art date
Application number
IL265700A
Other languages
English (en)
Hebrew (he)
Other versions
IL265700A (en
IL265700B1 (en
Original Assignee
Myovant Sciences Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL265700(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh, Takeda Pharmaceuticals Co filed Critical Myovant Sciences Gmbh
Publication of IL265700A publication Critical patent/IL265700A/en
Publication of IL265700B1 publication Critical patent/IL265700B1/en
Publication of IL265700B2 publication Critical patent/IL265700B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
IL265700A 2016-09-30 2019-03-28 N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4 -tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea and its uses IL265700B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402034P 2016-09-30 2016-09-30
US201662402055P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (3)

Publication Number Publication Date
IL265700A IL265700A (en) 2019-05-30
IL265700B1 IL265700B1 (en) 2023-03-01
IL265700B2 true IL265700B2 (en) 2023-07-01

Family

ID=60915460

Family Applications (2)

Application Number Title Priority Date Filing Date
IL265700A IL265700B2 (en) 2016-09-30 2019-03-28 N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4 -tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea and its uses
IL300580A IL300580B2 (en) 2016-09-30 2023-02-12 Methods for treating uterine fibroids and endometrial disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL300580A IL300580B2 (en) 2016-09-30 2023-02-12 Methods for treating uterine fibroids and endometrial disease

Country Status (24)

Country Link
US (4) US11033551B2 (OSRAM)
EP (2) EP4094766B1 (OSRAM)
JP (1) JP7043503B2 (OSRAM)
CN (1) CN110312512B (OSRAM)
AU (2) AU2017336363B2 (OSRAM)
BR (1) BR112019006227A2 (OSRAM)
CA (1) CA3038879A1 (OSRAM)
CY (1) CY1125254T1 (OSRAM)
DK (1) DK3518933T4 (OSRAM)
ES (2) ES2912929T5 (OSRAM)
FI (1) FI3518933T4 (OSRAM)
HR (1) HRP20220708T4 (OSRAM)
HU (2) HUE059101T2 (OSRAM)
IL (2) IL265700B2 (OSRAM)
LT (1) LT3518933T (OSRAM)
MD (1) MD3518933T4 (OSRAM)
MX (1) MX2019003726A (OSRAM)
NZ (1) NZ752916A (OSRAM)
PL (2) PL3518933T5 (OSRAM)
PT (1) PT3518933T (OSRAM)
RS (1) RS63300B2 (OSRAM)
SI (1) SI3518933T2 (OSRAM)
SM (1) SMT202200254T1 (OSRAM)
WO (1) WO2018060501A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3518933T4 (da) 2016-09-30 2025-04-22 Takeda Pharmaceuticals Co Fremgangsmåder til behandling af uterusfibromer og endometriose
FI3518932T3 (fi) 2016-09-30 2025-02-03 Sumitomo Pharma Switzerland Gmbh Eturauhassyövän hoito
KR20250117836A (ko) 2017-06-05 2025-08-05 깃세이 야쿠힌 고교 가부시키가이샤 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
MX2019014482A (es) 2017-06-05 2020-08-17 ObsEva SA Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación.
IL278082B2 (en) * 2018-04-19 2025-03-01 Abbvie Inc Methods of treating heavy menstrual bleeding
EP3873465B1 (en) 2018-10-29 2025-01-15 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
US20220305017A1 (en) * 2019-08-08 2022-09-29 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN115279769A (zh) * 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CN115175912B (zh) * 2019-10-10 2025-04-11 住友制药瑞士有限公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
BR112022016625A2 (pt) * 2020-02-19 2022-11-16 Aspira Womens Health Inc Composições para avaliação de endometriose tendo especificidade melhorada
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
JP2024540922A (ja) 2021-10-18 2024-11-06 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143669A1 (en) * 2013-03-15 2014-09-18 AbbVie Inc . Compositions for use in treating heavy menstrual bleeding and uterine fibroids

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US492839A (en) 1893-03-07 Key for brake-shoes
US402150A (en) 1889-04-30 Broadcast seed-sower
US528409A (en) 1894-10-30 Denis ahern
US402034A (en) 1889-04-23 Dumping-wagon
US402055A (en) 1889-04-23 Water-motor
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
CN1539836A (zh) 2000-02-29 2004-10-27 武田药品工业株式会社 制备噻吩并嘧啶衍生物的方法
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
ATE407679T1 (de) 2003-07-07 2008-09-15 Neurocrine Biosciences Inc Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
JPWO2007011072A1 (ja) 2005-07-22 2009-02-05 武田薬品工業株式会社 早発排卵の防止剤
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
KR101506750B1 (ko) 2007-04-06 2015-03-27 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀-방출 호르몬 수용체 길항제 및 그와 관련된 방법
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EP2582371B1 (en) 2010-06-16 2019-10-16 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
LT3415517T (lt) 2012-09-28 2022-06-10 Takeda Pharmaceutical Company Limited Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma
RS64377B1 (sr) 2015-02-26 2023-08-31 Takeda Pharmaceuticals Co Tableta koja sadrži derivat metoksiuree i čestice manitola
WO2017040841A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
FI3518932T3 (fi) 2016-09-30 2025-02-03 Sumitomo Pharma Switzerland Gmbh Eturauhassyövän hoito
DK3518933T4 (da) 2016-09-30 2025-04-22 Takeda Pharmaceuticals Co Fremgangsmåder til behandling af uterusfibromer og endometriose
KR20250117836A (ko) 2017-06-05 2025-08-05 깃세이 야쿠힌 고교 가부시키가이샤 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CN115175912B (zh) 2019-10-10 2025-04-11 住友制药瑞士有限公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
JP2024540922A (ja) 2021-10-18 2024-11-06 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143669A1 (en) * 2013-03-15 2014-09-18 AbbVie Inc . Compositions for use in treating heavy menstrual bleeding and uterine fibroids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, ROIVANT SCIENCES AND TAKEDA LAUNCH MYOVANT SCIENCES TO DEVELOP INNOVATIVE THERAPEUTICS FOR WOMEN'S HEALTH AND PROSTATE CANCER, 6 June 2016 (2016-06-06) *
REPORTSTACK,, ENDOMETRIOSIS - OPPORTUNITY ANALYSIS AND FORECASTS TO 2017, 4 February 2014 (2014-02-04) *

Also Published As

Publication number Publication date
NZ752916A (en) 2022-09-30
HUE059101T2 (hu) 2022-10-28
SI3518933T2 (sl) 2025-05-30
WO2018060501A3 (en) 2018-05-11
US11033551B2 (en) 2021-06-15
JP2019529575A (ja) 2019-10-17
PT3518933T (pt) 2022-05-10
RS63300B2 (sr) 2025-05-30
CA3038879A1 (en) 2018-04-05
CN110312512B (zh) 2023-05-09
EP4094766A1 (en) 2022-11-30
IL300580A (en) 2023-04-01
PL4094766T3 (pl) 2025-07-28
HUE072130T2 (hu) 2025-10-28
IL300580B2 (en) 2025-11-01
MD3518933T2 (ro) 2022-07-31
PL3518933T5 (pl) 2025-05-05
US20220370462A1 (en) 2022-11-24
EP3518933B1 (en) 2022-03-16
IL265700A (en) 2019-05-30
IL265700B1 (en) 2023-03-01
ES3018413T3 (es) 2025-05-16
US11793812B2 (en) 2023-10-24
EP4094766B1 (en) 2025-04-02
SMT202200254T1 (it) 2022-07-21
EP3518933B2 (en) 2025-02-26
US11957684B2 (en) 2024-04-16
AU2022241582B2 (en) 2024-06-13
DK3518933T4 (da) 2025-04-22
HRP20220708T4 (hr) 2025-04-25
LT3518933T (lt) 2022-06-10
US20190262346A1 (en) 2019-08-29
HRP20220708T1 (hr) 2022-07-22
CN110312512A (zh) 2019-10-08
MD3518933T4 (ro) 2025-10-31
PL3518933T3 (pl) 2022-06-20
ES2912929T5 (en) 2025-05-09
US20210401841A1 (en) 2021-12-30
SI3518933T1 (sl) 2022-06-30
AU2022241582A1 (en) 2022-10-27
IL300580B1 (en) 2025-07-01
AU2017336363B2 (en) 2022-08-04
DK3518933T3 (da) 2022-05-30
JP7043503B2 (ja) 2022-03-29
CY1125254T1 (el) 2024-02-16
ES2912929T3 (es) 2022-05-30
WO2018060501A2 (en) 2018-04-05
RS63300B1 (sr) 2022-07-29
EP3518933A2 (en) 2019-08-07
US20240165118A1 (en) 2024-05-23
AU2022241582C1 (en) 2024-11-28
AU2017336363A1 (en) 2019-05-16
BR112019006227A2 (pt) 2019-06-18
FI3518933T4 (fi) 2025-05-14
MX2019003726A (es) 2019-09-26

Similar Documents

Publication Publication Date Title
US11957684B2 (en) Treatment of heavy menstrual bleeding associated with uterine fibroids
US12336990B2 (en) Treatment of prostate cancer
EA041715B1 (ru) Способы лечения миомы матки и обильного менструального кровотечения
EA049363B1 (ru) Способы лечения эндометриоза и боли,связанной с эндометриозом
HK40116485A (en) Treatment of prostate cancer
EA043716B1 (ru) Лечение рака предстательной железы
HK40012837B (en) Methods of treating uterine fibroids and endometriosis